Authors
Latest:
The Shrinking CMO IndustryExits from the CMO industry are a more recent development that seems to be picking up momentum.
Latest:
FDA, Industry Face Challenges in the Year AheadUnprecedented policy and access issues threaten R&D momentum.
Latest:
FDA Speeds New Guidances to Inform Clinical Research During PandemicThe need for new therapies to treat coronavirus patients has prompted an onslaught of advisories from FDA clarifying how sponsors should assess and implement changes necessary to fit this new reality.
Latest:
Industry Slams Medicare Price Negotiation SchemeRecent lawsuits are challenging the constitutionality of provisions in the Inflation Reduction Act.
Latest:
New Year, Next Steps in Digital TransformationFive predictions on evolution of data and predictive insights that could be critical for pharma go-to-market strategies.
Latest:
January 2017: Small-Company Attention, Big-Company ResourcesGayle Johnston explains what makes CuraScript SD uniquely able to serve its broad range of customers.
Latest:
Partnering for Holistic SolutionsAs the healthcare landscape evolves, pharmaceutical companies are being driven to embrace new, unique partnerships to go beyond the pill, writes Weng Si Ho.
Latest:
A Brave New World: Optimizing Access in Wake of COVIDThe top changes necessary in planning and designing pharma market access plans, including a revamp of the payer-value equation at pivotal points in the product life cycle.
Latest:
Compliance and Consistency with FDA Required LabelingRuth Trzcienski's reviews FDA's new Procedural Guidance to help manufacturers ensure consistency with the FDA-required labelling.
Latest:
The Trouble with Pharma Partnerships ... And How to Fix ThemA new approach to reviving industry collaborations.
Latest:
Reducing the Risk of NoncomplianceThe key steps to easing rising complexity and cost factors.
Latest:
Reducing the Risk of NoncomplianceThe key steps to easing rising complexity and cost factors.
Latest:
CMED: The ‘Curupira’ of Brazil’s Pharma MarketOutlining one country’s unique price-setting model for novel drugs-and the resulting pre-launch strategies for manufacturers.
Latest:
CMED: The ‘Curupira’ of Brazil’s Pharma MarketOutlining one country’s unique price-setting model for novel drugs-and the resulting pre-launch strategies for manufacturers.
Latest:
CMED: The ‘Curupira’ of Brazil’s Pharma MarketOutlining one country’s unique price-setting model for novel drugs-and the resulting pre-launch strategies for manufacturers.
Latest:
Minimizing Liability with Export Control ComplianceBrooke Ringel and Eric McClafferty outline steps companies should take to ensure compliance with export controls.
Latest:
Leveraging Cognitive Search and Search-Based ApplicationsLaurent Fanichet outlines four ways pharma companies can use cognitive search and search-based applications to improve competitiveness.
Latest:
Precision Medicine and Big DataHow integrating next-generation sequencing data can advance efforts in immuno-oncology research.
Latest:
What First Amendment? FDA Remains Unfazed By Off-Label Communication IssuesAn FDA Memo addressing First Amendment legal issues regarding off-label use of medical products falls short of the necessary clarity, write Jamie Kendall and Alexandra Schulz.
Latest:
Securing the Pharma Supply Chain: Current Challenges and Key StepsJeff R. Livingstone outlines the critical steps necessary to ensure an agile, responsive and streamlined supply chain.
Latest:
Improving Customer Engagement: Why Your Data Could Be Letting You DownWhile it is foundational to commercial operations, most European life sciences companies are not getting what they need from their customer data, writes Guillame Roussel.
Latest:
Price Transparency Regulations are Accelerating Market Disruption. Are You Prepared?As pricing transparency regulations and COVID-19 accelerate market disruption and changes in consumer behavior demand new engagement models, how can your organization prepare for the powerful shift toward more consumer-centric pricing transparency?
Latest:
The Lengthening Arm of PharmacovigilanceExperts debate the practice’s rise up the life sciences agenda.
